- Report
- January 2026
- 197 Pages
Global
From €3177EUR$3,545USD£2,754GBP
€3530EUR$3,939USD£3,060GBP
- Report
- March 2026
- 194 Pages
Global
From €5242EUR$5,850USD£4,544GBP
- Report
- March 2026
- 183 Pages
Global
From €5242EUR$5,850USD£4,544GBP
- Report
- February 2026
- 250 Pages
Global
From €4024EUR$4,490USD£3,488GBP
- Report
- January 2026
- 185 Pages
Global
From €4033EUR$4,500USD£3,496GBP
- Report
- August 2025
- 183 Pages
Global
From €3177EUR$3,545USD£2,754GBP
€3530EUR$3,939USD£3,060GBP
- Report
- December 2025
- 120 Pages
Global
From €5332EUR$5,950USD£4,622GBP
- Report
- February 2026
- 250 Pages
Global
From €4024EUR$4,490USD£3,488GBP
- Report
- June 2025
- 150 Pages
Global
From €2419EUR$2,699USD£2,097GBP
- Report
- June 2024
- 200 Pages
Global
From €7124EUR$7,950USD£6,176GBP
- Report
- April 2023
- 118 Pages
Global
From €4257EUR$4,750USD£3,690GBP
- Report
- March 2025
- 142 Pages
Global
From €3584EUR$3,999USD£3,106GBP
- Report
- April 2024
- 38 Pages
Global
From €3580EUR$3,995USD£3,103GBP
- Report
- November 2022
- 288 Pages
Global
From €3226EUR$3,600USD£2,797GBP
- Report
- December 2022
- 34 Pages
Global
From €1792EUR$2,000USD£1,554GBP
- Report
- February 2024
- 105 Pages
Global
From €3500EUR$4,184USD£3,140GBP

Methicillin-resistant Staphylococcus aureus (MRSA) is a type of bacteria that is resistant to many antibiotics. As a result, it is a major cause of infections in hospitals and other healthcare settings. To combat this, the MRSA drug market has developed a range of treatments, including antibiotics, antiseptics, and vaccines. These drugs are designed to target the bacteria and reduce the risk of infection.
The MRSA drug market is highly competitive, with a range of companies offering different treatments. Some of the major players in the market include Pfizer, Merck, GlaxoSmithKline, Sanofi, and Novartis. These companies are constantly developing new treatments to combat the spread of MRSA and other infectious diseases. Show Less Read more